Neurology’s false choice: symptomatic vs. disease-modifying

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

Even as many drug developers celebrate anti-amyloid antibodies as the start of a new era of disease-modifying treatments for dementia, a set of up-and-coming biotechs aims to tear down the distinction between symptomatic and disease-modifying therapy. ...